S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

$9.55
+0.69 (+7.79%)
(As of 03/1/2024 ET)
Today's Range
$8.76
$9.77
50-Day Range
$4.90
$10.62
52-Week Range
$3.89
$16.20
Volume
497,986 shs
Average Volume
423,589 shs
Market Capitalization
$217.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
16.2% Downside
$8.00 Price Target
Short Interest
Bearish
7.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.33mentions of Inovio Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.68) to ($3.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.13 out of 5 stars

Medical Sector

626th out of 951 stocks

Surgical & Medical Instruments Industry

65th out of 89 stocks


INO stock logo

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Stock Price History

INO Stock News Headlines

Novavax’s dispute resolution and upcoming earnings call (INO)
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Inovio Pharmaceuticals (INO) to Release Earnings on Wednesday
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Inovio Pharmaceuticals Inc (0A43)
Why Is Inovio Pharmaceuticals (INO) Stock Down Today?
INOVIO Plans To Submit BLA For INO-3107 In H2 - Quick Facts
Q3 2023 Inovio Pharmaceuticals Inc Earnings Call
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2023
Today
3/03/2024
Next Earnings (Confirmed)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INO
Employees
184
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$12.00
Low Stock Price Target
$4.00
Potential Upside/Downside
-16.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-279,820,000.00
Net Margins
-19,271.31%
Pretax Margin
-19,271.31%

Debt

Sales & Book Value

Annual Sales
$10.26 million
Book Value
$10.70 per share

Miscellaneous

Free Float
22,308,000
Market Cap
$217.17 million
Optionable
Optionable
Beta
1.05

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jacqueline E. Shea Ph.D. (Age 58)
    CEO, President & Director
    Comp: $1.08M
  • Mr. Peter D. KiesMr. Peter D. Kies (Age 61)
    Chief Financial Officer
    Comp: $688.72k
  • Dr. Laurent M. Humeau Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $673.59k
  • Thomas Hong
    Manager of Investor Relations
  • Mr. Robert L. Crotty J.D. (Age 50)
    General Counsel & Chief Compliance Officer
  • Mr. E. J. Brandreth MBA
    Senior Vice President of Quality Assurance
  • Dr. Jeffrey Skolnik
    Senior Vice President of Clinical Development
  • Mr. Robert J. Juba Jr.
    Senior Vice President of Biological Manufacturing & Clinical Supply Management
  • Mr. Stephen Kemmerrer M.B.A.
    P.E., Senior Vice President of Engineering Development
  • Mr. Shawn D. Bridy M.A.
    M.B.A., Senior Vice President of Business Development














INO Stock Analysis - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INO shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price target for 2024?

2 brokerages have issued 12-month price objectives for Inovio Pharmaceuticals' stock. Their INO share price targets range from $4.00 to $12.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests that the stock has a possible downside of 16.2%.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2024?

Inovio Pharmaceuticals' stock was trading at $6.12 on January 1st, 2024. Since then, INO stock has increased by 56.0% and is now trading at $9.55.
View the best growth stocks for 2024 here
.

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,740,000 shares, an increase of 21.7% from the January 31st total of 1,430,000 shares. Based on an average daily trading volume, of 394,900 shares, the short-interest ratio is currently 4.4 days. Approximately 7.8% of the company's shares are sold short.
View Inovio Pharmaceuticals' Short Interest
.

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our INO earnings forecast
.

How can I listen to Inovio Pharmaceuticals' earnings call?

Inovio Pharmaceuticals will be holding an earnings conference call on Wednesday, March 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the consensus estimate of ($1.68) by $0.12. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.20 million. Inovio Pharmaceuticals had a negative net margin of 19,271.31% and a negative trailing twelve-month return on equity of 84.52%. During the same quarter in the previous year, the business earned ($5.52) EPS.

When did Inovio Pharmaceuticals' stock split?

Shares of Inovio Pharmaceuticals reverse split before market open on Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (86.92%), GSA Capital Partners LLP (16.70%), Northern Trust Corp (2.44%), Green Alpha Advisors LLC (0.17%), Verition Fund Management LLC (0.66%) and Keystone Financial Group (0.54%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INO) was last updated on 3/3/2024 by MarketBeat.com Staff